Want to see ALDX full AI Analyst Report?
Total Valuation
Aldeyra Therapeutics has a market cap or net worth of $110.39M. The enterprise value is $60.90M.
Market Cap$110.39M
Enterprise Value$60.90M
Share Statistics
Aldeyra Therapeutics has 60,321,068 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,321,068
Owned by Insiders3.66%
Owned by Institutions21.91%
Financial Efficiency
Aldeyra Therapeutics’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -58.99%.
Return on Equity (ROE)-0.76
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-58.99%
Return on Capital Employed (ROCE)-0.80
Revenue Per Employee0.00
Profits Per Employee-4.23M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aldeyra Therapeutics is ―. Aldeyra Therapeutics’s PEG ratio is 0.23.
PE Ratio―
PS Ratio0.00
PB Ratio7.03
Price to Fair Value7.03
Price to FCF-9.33
Price to Operating Cash Flow-4.92
PEG Ratio0.23
Income Statement
In the last 12 months, Aldeyra Therapeutics had revenue of 0.00 and earned -33.85M in profits. Earnings per share was -0.56.
Revenue0.00
Gross Profit0.00
Operating Income-35.27M
Pretax Income-33.85M
Net Income-33.85M
EBITDA-31.69M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was -25.99M and capital expenditures -4.00, giving a free cash flow of -25.99M billion.
Operating Cash Flow-25.99M
Free Cash Flow-25.99M
Free Cash Flow per Share-0.43
Dividends & Yields
Aldeyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.60
52-Week Price Change-47.84%
50-Day Moving Average1.71
200-Day Moving Average3.88
Relative Strength Index (RSI)51.46
Average Volume (3m)1.04M
Important Dates
Aldeyra Therapeutics upcoming earnings date is Jul 31, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 31, 2026
Ex-Dividend Date―
Financial Position
Aldeyra Therapeutics as a current ratio of 2.58, with Debt / Equity ratio of 36.80%
Current Ratio2.58
Quick Ratio2.58
Debt to Market Cap0.05
Net Debt to EBITDA1.72
Interest Coverage Ratio-18.51
Taxes
In the past 12 months, Aldeyra Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aldeyra Therapeutics EV to EBITDA ratio is -8.10, with an EV/FCF ratio of -7.69.
EV to Sales0.00
EV to EBITDA-8.10
EV to Free Cash Flow-7.69
EV to Operating Cash Flow-7.69
Balance Sheet
Aldeyra Therapeutics has $65.00M in cash and marketable securities with $15.51M in debt, giving a net cash position of $49.49M billion.
Cash & Marketable Securities$65.00M
Total Debt$15.51M
Net Cash$49.49M
Net Cash Per Share$0.82
Tangible Book Value Per Share$0.74
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aldeyra Therapeutics is $2.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$2.00
Price Target Upside11.11% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast53.00%